Divi’s Laboratories Limited has announced its unaudited consolidated results for the quarter ended December 31, 2025, reflecting consistent revenue growth and improved performance over the nine-month period of FY26.

Q3 FY26 Consolidated Performance

For the December quarter, consolidated total income rose to ₹2,692 crore, compared with ₹2,401 crore in the same quarter of the previous financial year, marking steady year-on-year growth.

Profit Before Tax (PBT) stood at ₹780 crore during the quarter, after factoring in labour code-related expenses of ₹74 crore. In comparison, PBT was ₹726 crore in Q3 FY25.

Despite higher pre-tax earnings, Profit After Tax (PAT) slightly declined to ₹583 crore from ₹589 crore reported in the year-ago quarter. The company recorded a foreign exchange gain of ₹19 crore during the period, higher than the ₹10 crore gain in the corresponding quarter last year.

Nine-Month FY26 Consolidated Results

For the nine months ended December 31, 2025, Divi’s Laboratories reported consolidated total income of ₹8,081 crore, up from ₹7,041 crore in the corresponding period of the previous year.

Profit Before Tax for the period increased to ₹2,425 crore after accounting for labour code impacts, compared with ₹2,052 crore in the same period last year.

Net profit showed a strong improvement, with Profit After Tax rising to ₹1,817 crore from ₹1,529 crore a year earlier. Foreign exchange gains also supported earnings during the nine-month period, increasing to ₹121 crore from ₹38 crore in the previous year’s comparable period.

Standalone Financial Highlights

On a standalone basis, total income for Q3 FY26 came in at ₹2,665 crore, up from ₹2,379 crore in Q3 FY25.

Standalone Profit After Tax for the quarter stood at ₹598 crore, marginally higher than ₹594 crore reported in the same quarter last year.

For the nine-month period, standalone income reached ₹7,947 crore. Standalone PAT rose to ₹1,851 crore, compared with ₹1,542 crore in the previous financial year, indicating improved operational performance.

Summary

Divi’s Laboratories delivered steady revenue growth in Q3 FY26, with consolidated income rising year-on-year. While quarterly net profit saw a slight dip, pre-tax earnings improved despite labour code-related adjustments. The nine-month performance was notably stronger, with significant growth in both revenue and profitability, supported in part by higher foreign exchange gains. Standalone results also reflected consistent operational strength across the period.

This article is intended solely for educational and informational purposes. The securities or companies mentioned are provided as examples and should not be considered as recommendations. Nothing contained herein constitutes personal financial advice or investment recommendations. Readers are advised to conduct their own research and consult a qualified financial advisor before making any investment decisions.

Investments in securities markets are subject to market risks. Please read all related documents carefully before investing.